Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARCT
DateTimeSourceHeadlineSymbolCompany
05/15/20243:01PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:01PMBusiness WireArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/25/20243:01PMBusiness WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/07/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/07/20243:01PMBusiness WireArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/26/20248:00AMBusiness WireArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/23/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/22/20247:30AMBusiness WireArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/20/20248:00AMBusiness WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/05/20247:30AMPR Newswire (US)New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/05/20247:30AMBusiness WireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/21/20237:00AMBusiness WireCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/21/20237:00AMPR Newswire (US)CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/19/20237:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/04/20237:30AMBusiness WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/28/20237:05AMPR Newswire (US)Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/28/20237:00AMBusiness WireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/27/20238:13AMDow Jones NewsArcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/27/20237:30AMBusiness WireArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/15/20237:51AMIH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/14/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/14/20233:01PMBusiness WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/25/20233:01PMBusiness WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/23/20233:01PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/04/20237:30AMBusiness WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/26/20233:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/26/20237:30AMBusiness WireArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/19/20237:30AMBusiness WireStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT